NCT04980534 is a NA clinical trial of Viusid and Asbrip in Covid19, sponsored by Catalysis SL.

Who is sponsoring NCT04980534?

NCT04980534 is sponsored by Catalysis SL.

What drugs are being tested in NCT04980534?

Interventions in NCT04980534: Viusid and Asbrip, COVID-19 Standard Therapy.

What condition does NCT04980534 study?

NCT04980534 studies Covid19, COVID-19 Pneumonia, COVID-19 Respiratory Infection, Viral Infection, Respiratory Tract Infections, Infection, Coronavirus, SARS-CoV2 Infection.

Is NCT04980534 still recruiting?

NCT04980534 is currently completed. Last updated 13 April 2022.

Last reviewed 2022-04-13 · How we verify

NCT04980534

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of the Effectiveness of Therapy for Patients With Covid-19 Using Food Supplements Viusid + Asbrip

Completed NA Last updated 13 April 2022

What this trial tests

NA trial testing Viusid and Asbrip in Covid19 in 80 participants. Completed in 15 September 2021.

Timeline

8 January 2021

Primary endpoint
30 June 2021

15 September 2021

Quick facts

Lead sponsor	Catalysis SL
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	supportive care
Enrollment	80
Start date	8 January 2021
Primary completion	30 June 2021
Estimated completion	15 September 2021
Sites	3 locations across Kazakhstan

Drugs / interventions tested

Viusid and Asbrip
COVID-19 Standard Therapy — full drug profile →

Conditions studied

Covid19 — all drugs for Covid19 →
COVID-19 Pneumonia — all drugs for COVID-19 Pneumonia →
COVID-19 Respiratory Infection — all drugs for COVID-19 Respiratory Infection →
Viral Infection — all drugs for Viral Infection →

Sponsor

Catalysis SL — full company profile →

Who can join

Adults 18 to 85, any sex, with Covid19 or COVID-19 Pneumonia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a two-arm, randomized, open label, monocenter, controlled study to evaluate the safety and efficacy of Viusid plus Asbrip in patients with mild and moderate symptoms of respiratory illness caused by Coronavirus 2019 infection.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Viusid and Asbrip

Trials testing the same drug.

NCT04407182 — Safety and Efficacy of Viusid and Asbrip in Hospitalized Patients Infected by SARS-Cov-2 With COVID-19 · Phase 2 · completed

Other recruiting trials for Covid19

Currently open trials in the same condition.

NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting

Other Catalysis SL trials

Trials by the same sponsor.

NCT07179237 — Efficacy of Carminal in Helicobacter Pylori Gastritis · Phase 2 · recruiting
NCT06363201 — Effect and Safety of Ocoxin Oral Solution on the Quality of Life of Paediatric Patients With Advanced Stage Solid Tumour · NA · not yet recruiting
NCT05916911 — Evaluation Of The Efficacy Of The Combination Of GLIZIGEN® Oral Solution 1/Day And Vaginal Gel 1/Night For 2 Months In P · Phase 4 · unknown
NCT06496087 — Evaluation of DEPREXIL in Patients With Clinical Depression Through Psychological and Neuroendocrine Assessment · NA · completed
NCT06361992 — Efficacy and Safety of Blue Cap for the Treatment of Atopic Dermatitis in Children · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04980534 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Catalysis SL
Last refreshed: 13 April 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04980534.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing